Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
03 October 2019 | Story Ruan Bruwer | Photo Gallo Images
Lappies Labuschagne
Lappies Labuschagné got his first rugby contract with the Cheetahs after impressing for the Shimlas. He is now playing for Japan – the first Shimla to do so.

Former Shimla Lappies Labuschagné made his ex-coach Jaco Swanepoel proud when he was recently included in the Japan Rugby World Cup (RWC) squad.

Labuschagné, made his debut for Japan on 28 September as captain shortly before the tournament, which is currently under way there, then led Japan to a historic win over Ireland, the world’s fourth-ranked team.


Labuschagné has been playing his rugby in Japan since 2016. Previously, he played for the Shimlas between 2009 and 2012 and captained the team in 2012. At that time, Swanepoel was the head coach of the Shimlas. 

“I’m extremely glad that he got his chance to play in the World Cup, just to prove that he can compete at that level. It was wonderful to see the leadership we knew he had on Saturday,” Swanepoel said.

He believes Labuschagné was unlucky not to have played for the Springboks. In 2013, he was called up to the South African squad, but failed to force his way into the congested Springbok back row. 

“Subjectivity in team selection was the reason that he wasn’t considered. He deserved to be selected and he worked extremely hard. I don’t know of a player who worked harder than him. Nobody wanted to work out with him in the gymnasium, because he always put in extra effort. That made him special.”

Swanepoel describes Labuschagné as a “very special person”.

“Lappies the human being is perhaps a little bit better than Lappies the rugby player.”  

“Hopefully we can get a Japan rugby jersey from him to display in the Shimla room soon,” Swanepoel added.

Labuschagné isn’t the only former Kovsie at the RWC. In the Springbok management team, Rassie Erasmus (head coach), Jacques Nienaber (defence coach), and Vivian Verwant (physiotherapist) are also former Kovsies.


News Archive

Heart-valve studies receive international recognition
2017-07-11

 Description: Heart-valve studies  Tags: Heart-valve studies  

Prof Francis Smit, Head of the Department of
Cardiothoracic Surgery at the UFS, and Manager of the
Robert WM Frater Cardiovascular Research Centre, with
Kyle Davis, Mechanical Engineer at the centre.

Photo: Rulanzen Martin

Three heart-valve studies which have been developed at the Robert WM Frater Cardiovascular Research Centre at the School of Medicine at the University of the Free State (UFS) were recently presented in Monte Carlo at the conference of the prestigious global Heart Valve Society (HVS).

These studies are all headed by Prof Francis Smit, Head of the Department of Cardiothoracic Surgery at the UFS, and Manager of the Robert WM Frater Cardiovascular Research Centre.
Prof Smit says the HVS is a combination of the former heart-valve societies of Europe and the US. “Studies on heart-valve disease, heart-valve-related products and operations, as well as the design and development of new valves were presented. There are both clinical and development divisions.

He says the study in which the hemodynamics of their redesigned mechanical poppet valve was compared to a commercial bi-leaflet mechanical heart valve, was named as the best poster presentation in the experimental valve development and numerical flow dynamics division. The study, which was presented by Kyle Davis, mechanical engineer at the centre, competed against some of the best heart-valve research units in the world.

The redesigned valve, based on the 1960s Cape Town poppet valve, has the potential to provide a low-cost solution for mechanical heart-valve replacement. It is possible to produce the titanium ring with 3-D printers and is, together with the silicon poppet valve, extremely inexpensive compared to current mechanical valve-manufacturing processes.
The advantages of this valve over current mechanical valves is that, due to the effective and laminar flow characteristics, as well as the simple locking mechanisms, there is a reduced chance of valve thrombosis, and the need for anti-clotting drugs is therefore limited.

It was also confirmed that the new valve more than meets the published FDA (Federal Drug Agency) requirements, which determine the minimum standards of valves for human use in the US.

The redesigned valve also has a very low platelet activation impact, which is responsible for platelet thrombosis and leads to valve thrombosis or strokes. This valve is another heart-valve project by the centre, which is also in the process of evaluating a tri-leaflet polyurethane valve developed by them.


We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept